Eisai Co., Ltd. - Product Pipeline Review - 2014

Published: Sep, 2014 | Pages: 161 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Eisai Co., Ltd. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Eisai Co., Ltd. - Product Pipeline Review - 2014', provides an overview of the Eisai Co., Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Eisai Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Eisai Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Eisai Co., Ltd.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Eisai Co., Ltd.'s pipeline products

Reasons to buy

- Evaluate Eisai Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Eisai Co., Ltd. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Eisai Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Eisai Co., Ltd. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Eisai Co., Ltd.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Eisai Co., Ltd. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Eisai Co., Ltd. Snapshot 6
Eisai Co., Ltd. Overview 6
Key Information 6
Key Facts 6
Eisai Co., Ltd. - Research and Development Overview 7
Key Therapeutic Areas 7
Eisai Co., Ltd. - Pipeline Review 13
Pipeline Products by Stage of Development 13
Pipeline Products - Monotherapy 14
Pipeline Products - Combination Treatment Modalities 15
Pipeline Products - Partnered Products 16
Pipeline Products - Out-Licensed Products 18
Eisai Co., Ltd. - Pipeline Products Glance 20
Eisai Co., Ltd. - Late Stage Pipeline Products 20
Eisai Co., Ltd. - Clinical Stage Pipeline Products 23
Eisai Co., Ltd. - Early Stage Pipeline Products 25
Eisai Co., Ltd. - Drug Profiles 27
cinitapride 27
eribulin mesylate 28
lenvatinib 32
lorcaserin hydrochloride 36
mitiglinide 39
perampanel 41
clevudine 43
donepezil hydrochloride Patch 45
(diclofenac sodium + eperisone) 47
avatrombopag 48
donepezil hydrochloride 50
rufinamide 51
mecobalamin 53
4-Peptide Melanoma Vaccine 54
BAN-2401 55
decitabine 57
denileukin diftitox 60
E-1224 62
E-2006 64
E-6005 65
E-7016 66
E-7820 67
indisulam 68
rabeprazole sodium 69
RAD-1901 71
bexarotene 73
E-6011 75
E-7438 76
E-7449 77
golvatinib 78
golvatinib + lenvatinib 80
E-2212 82
E-2609 83
E-3710 84
E-6007 85
E-6201 86
eribulin mesylate liposomal 88
PRI-724 89
AT-791 91
E-1210 92
E-1211 93
E-2072 94
E-2508 95
E-5539 96
E-6446 97
ER-358063 98
ER-409903 99
ER-410660 100
ER-417258 101
ER-886046 102
ER-901356 103
Monoclonal Antibody to Inhibit CCL20 for Arthritis and Contact Hypersensitivity 104
Small Molecule to Antagonize Corticotropin-Releasing Factor 1 Receptor for Anxiety Disorders 105
Small Molecule to Inhibit Cytidine Deaminase for Cancer 106
Small Molecule to Inhibit GWT1 Protein for Malaria 107
Drugs for Chagas Disease 108
Drugs for Tuberculosis 109
Small Molecules for Lymphatic Filariasis and Onchocerciasis 110
Small Molecules for Malaria 111
Eisai Co., Ltd. - Pipeline Analysis 112
Eisai Co., Ltd. - Pipeline Products by Target 112
Eisai Co., Ltd. - Pipeline Products by Route of Administration 115
Eisai Co., Ltd. - Pipeline Products by Molecule Type 116
Eisai Co., Ltd. - Pipeline Products by Mechanism of Action 117
Eisai Co., Ltd. - Recent Pipeline Updates 121
Eisai Co., Ltd. - Dormant Projects 146
Eisai Co., Ltd. - Discontinued Pipeline Products 148
Discontinued Pipeline Product Profiles 148
Eisai Co., Ltd. - Company Statement 152
Eisai Co., Ltd. - Locations And Subsidiaries 153
Head Office 153
Other Locations & Subsidiaries 153
Appendix 156
Methodology 156
Coverage 156
Secondary Research 156
Primary Research 156
Expert Panel Validation 156
Contact Us 157
Disclaimer 157

List of Tables
Eisai Co., Ltd., Key Information 10
Eisai Co., Ltd., Key Facts 10
Eisai Co., Ltd. - Pipeline by Indication, 2014 13
Eisai Co., Ltd. - Pipeline by Stage of Development, 2014 17
Eisai Co., Ltd. - Monotherapy Products in Pipeline, 2014 18
Eisai Co., Ltd. - Combination Treatment Modalities in Pipeline, 2014 19
Eisai Co., Ltd. - Partnered Products in Pipeline, 2014 20
Eisai Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2014 21
Eisai Co., Ltd. - Out-Licensed Products in Pipeline, 2014 22
Eisai Co., Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2014 23
Eisai Co., Ltd. - Pre-Registration, 2014 24
Eisai Co., Ltd. - Filing rejected/Withdrawn, 2014 25
Eisai Co., Ltd. - Phase III, 2014 26
Eisai Co., Ltd. - Phase II, 2014 27
Eisai Co., Ltd. - Phase I, 2014 28
Eisai Co., Ltd. - Preclinical, 2014 29
Eisai Co., Ltd. - Discovery, 2014 30
Eisai Co., Ltd. - Pipeline by Target, 2014 117
Eisai Co., Ltd. - Pipeline by Route of Administration, 2014 119
Eisai Co., Ltd. - Pipeline by Molecule Type, 2014 120
Eisai Co., Ltd. - Pipeline Products by Mechanism of Action, 2014 122
Eisai Co., Ltd. - Recent Pipeline Updates, 2014 125
Eisai Co., Ltd. - Dormant Developmental Projects,2014 150
Eisai Co., Ltd. - Discontinued Pipeline Products, 2014 152
Eisai Co., Ltd., Subsidiaries 157